← PALVELLA THERAPEUTICS, INC. (PVLA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
PALVELLA THERAPEUTICS, INC. (PVLA)
Pharmaceutical Preparations · market cap $2.2B · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-10 (est.)
Earnings
Pipeline
2
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Palvella Therapeutics (PVLA) is a small-cap pharma (14 employees, ~$2.2B market cap) with two Phase 3 assets: QTORIN 3.9% Rapamycin Anhydrous Gel for Microcystic Lymphatic Malformation (MLM) and PTX-022 for Pachyonychia Congenita (PC). The company carries $206.4M in cash with an estimated 57-month runway and no disclosed revenue in 2025, suggesting it remains pre-commercial and dependent on pipeline readouts.
The catalyst path
- 2026-11-10 (est.)Earningsimp 5/10
- 2027-08-15 (est.)Phase 2 · PTX-022imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| QTORIN 3.9% Rapamycin Anhydrous Gel | Phase 3 | Microcystic Lymphatic Malformation |
| PTX-022 | Phase 3 | Pachyonychia Congenita |
Price & technical context
3-month
-9.6%
6-month
+10.3%
12-month
+109.9%
52-wk range
$62.63–$158.13
vs 50-day MA
-10.9%
vs 200-day MA
+7.4%
Realized vol
89.9%
Max drawdown
-33.0%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PVLA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.